Literature DB >> 7041539

Criteria for analyzing interactions between biologically active agents.

M C Berenbaum.   

Abstract

Mesh：

Substances：

Year:  1981        PMID： 7041539     DOI： 10.1016/s0065-230x(08)60912-4

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN： 0065-230X            Impact factor:   6.242


× No keyword cloud information.
  114 in total

1.  Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.

Authors:  Annette Wunderlich; Silvia Roth; Annette Ramaswamy; Brandon H Greene; Cornelia Brendel; Ulrike Hinterseher; Detlef K Bartsch; Sebastian Hoffmann
Journal:  Endocrine       Date:  2012-04-05       Impact factor: 3.633

2.  Implications and problems in analysing cytotoxic activity of hydroxyurea in combination with a potential inhibitor of ribonucleotide reductase.

Authors:  G Nocentini; A Barzi; P Franchetti
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  The scientific assessment of combined effects of risk factors: different approaches in experimental biosciences and epidemiology.

Authors:  Wolfgang Boedeker; Thomas Backhaus
Journal:  Eur J Epidemiol       Date:  2010-05-22       Impact factor: 8.082

4.  Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.

Authors:  Ashley E Ross; Ashkan Emadi; Luigi Marchionni; Paula J Hurley; Brian W Simons; Edward M Schaeffer; Milena Vuica-Ross
Journal:  BJU Int       Date:  2010-12-22       Impact factor: 5.588

5.  CD6 synergistic co-stimulation promoting proinflammatory response is modulated without interfering with the activated leucocyte cell adhesion molecule interaction.

Authors:  P Nair; R Melarkode; D Rajkumar; E Montero
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

6.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

7.  Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.

Authors:  A Etxabe; M C Lara-Castillo; J M Cornet-Masana; A Banús-Mulet; M Nomdedeu; M A Torrente; M Pratcorona; M Díaz-Beyá; J Esteve; R M Risueño
Journal:  Leukemia       Date:  2017-02-14       Impact factor: 11.528

8.  Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Authors:  Salvia Jain; Abigail Washington; Rebecca Karp Leaf; Parul Bhargava; Rachael A Clark; Thomas S Kupper; Dina Stroopinsky; Athalia Pyzer; Leandra Cole; Myrna Nahas; Arie Apel; Jacalyn Rosenblatt; Jon Arnason; Donald Kufe; David Avigan
Journal:  Mol Cancer Ther       Date:  2017-07-20       Impact factor: 6.261

9.  Multicompartment models of cancer chemotherapy incorporating resistant cell populations.

Authors:  H N Duc; P M Nickolls
Journal:  J Pharmacokinet Biopharm       Date:  1987-04

10.  Drug interaction: focusing on response surface models.

Authors:  Soo-Il Lee
Journal:  Korean J Anesthesiol       Date:  2010-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.